Evidence map›Paper›PMID 31859456›Full record

ArticleJournal of applied clinical medical physics2020

FFF-VMAT for SBRT of lung lesions: Improves dose coverage at tumor-lung interface compared to flattened beams.

Damodar Pokhrel, Matthew Halfman, Lana Sanford

Open access · goldAbstract read
In one paragraph

Article in Journal of applied clinical medical physics, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
32citing papers in PubMed, 1 pooled it
6.9field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

32 citing papers in PubMed, 1 synthesis or guideline pooled it, 48 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Comparison of the dose distribution of the VMAT radiotherapy technique depending on the beam used: FFF-X10MV and FFF-X15MV.Reports of practical oncology and radiotherapy : journal of Greatpoland Cancer Center in Poznan and Polish Society of Radiation Oncology · 2023
    Article
  13. Article
  14. Planning issues on linac-based stereotactic radiotherapy.World journal of clinical cases · 2022
    Review
  15. Review
  16. Article
  17. Article
  18. A single centre evaluation of the 2019 UK SABR consortium guidelines for primary lung cancer: correlation between Prescription Dose Spillage and inverse Paddick Conformity Index.Reports of practical oncology and radiotherapy : journal of Greatpoland Cancer Center in Poznan and Polish Society of Radiation Oncology · 2022
    Article
  19. Article
  20. Using FFF Beams to Improve the Therapeutic Ratio of Lung SBRT.Journal of radiotherapy in practice · 2021
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Damodar PokhrelDepartment of Radiation Medicine, Medical Physics Graduate Program, University of Kentucky, Lexington, KY, USA.
Matthew HalfmanDepartment of Radiation Medicine, Medical Physics Graduate Program, University of Kentucky, Lexington, KY, USA.
Lana SanfordDepartment of Radiation Medicine, Medical Physics Graduate Program, University of Kentucky, Lexington, KY, USA.
University of Kentucky · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeTo quantify the differences in dosimetry as a function of ipsilateral lung density and treatment delivery parameters for stereotactic, single dose of volumetric modulated arc therapy (VMAT) lung stereotactic body radiation therapy (SBRT) delivered with 6X flattening filter free (6X-FFF) beams compared to traditional flattened 6X (6X-FF) beams. MATERIALS/

methodsThirteen consecutive early stage I-II non-small-cell-lung cancer (NSCLC) patients were treated with highly conformal noncoplanar VMAT SBRT plans (3-6 partial arcs) using 6X-FFF beam and advanced Acuros-based dose calculations to a prescription dose of 30 Gy in one fraction to the tumor margin. These clinical cases included relatively smaller tumor (island tumors) sizes (2.0-4.2 cm diameters) and varying average ipsilateral lung densities between 0.14 g/cc and 0.34 g/cc. Treatment plans were reoptimized with 6X-FF beams for identical beam/arc geometries and planning objectives. For same target coverage, the organs-at-risk (OAR) dose metrics as a function of ipsilateral lung density were compared between 6X-FFF and 6X-FF plans. Moreover, monitor units (MU), beam modulation factor (MF) and beam-on time (BOT) were evaluated.

resultsBoth plans met the RTOG-0915 protocol compliance. The ipsilateral lung density and the tumor location heavily influenced the treatment plans with 6X-FFF and 6X-FF beams, showing differences up to 12% for the gradient indices. For similar target coverage, 6X-FFF beams showed better target conformity, lower intermediate dose-spillage, and lower dose to the OAR. Additionally, BOT was reduced by a factor of 2.3 with 6X-FFF beams compared to 6X-FF beams.

conclusionWhile prescribing dose to the tumor periphery, 6X-FFF VMAT plans for stereotactic single-dose lung SBRT provided similar target coverage with better dose conformity, superior intermediate dose-spillage (improved dose coverage at tumor interface), and improved OAR sparing compared to traditional 6X-FF beams and significantly reduced treatment time. The ipsilateral lung density and tumor location considerably affected dose distributions requiring special attention for clinical SBRT plan optimization on a per-patient basis. Clinical follow up of these patients for tumor local-control rate and treatment-related toxicities is in progress.

Indexed as

Carcinoma, Non-Small-Cell LungHumansImaging, Three-DimensionalLung NeoplasmsOrgans at RiskPrognosisRadiosurgeryRadiotherapy DosageRadiotherapy, Intensity-ModulatedRadiotherapy Planning, Computer-AssistedFFF-beamlung SBRTnoncoplanar VMATRTOG-0915single-dose

Identifiers

PMID31859456
PMCPMC6964748
OpenAlexW2996294602

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.